<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181193</url>
  </required_header>
  <id_info>
    <org_study_id>SOR504110CTIL</org_study_id>
    <nct_id>NCT01181193</nct_id>
  </id_info>
  <brief_title>Vitamin D for Treatment of Glioblastoma Multiforme</brief_title>
  <official_title>High-Dose Vitamin D in Combination With Chemoradiotherapy in the Treatment of Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is non-randomized phase 2 study to assess efficacy and toxicity of long term high dose&#xD;
      vitamin D3 given concurrently with chemo-radiotherapy (CCRT) containing temozolomide followed&#xD;
      by adjuvant chemotherapy (ACT) with temozolomide in patients with newly diagnosed&#xD;
      glioblastoma multiforme GBM). Preoperative diagnosis of GBM will be based on magnetic&#xD;
      resonance imaging (MRI) brain scan. All patient will underwent craniotomy with partial or&#xD;
      total resection of a visible tumour mass. All patients will be planned for postoperative&#xD;
      three-dimensional conformal RT (3-DCRT) or intensity-modulated RT (IMRT) to residual tumour&#xD;
      and/or resection bed. A total RT dose of 54-60 Gy will be delivered using 2 Gy daily&#xD;
      fractions given over 5 days a week. Daily chemotherapy with temozolomide in the dose of 75&#xD;
      mg/m2/day will be started at the first day of RT, and will be continued for entire period of&#xD;
      RT inclusive week-end breaks. ACT will contain 6 cycles of oral temozolomide 150-200&#xD;
      mg/m2/day given for 5 days every 4 weeks. Oral vitamin D3 will be administered in daily dose&#xD;
      of 4000 IU. Vitamin D3 therapy will be started 1 week prior to commencing CCRT, and will be&#xD;
      terminated immediately after completing last cycle of ACT. MRI scan of the brain will be&#xD;
      performed at 4 months after completing CCRT, and than will be repeated every 4 months for&#xD;
      first 2 years, and every 6 months for subsequent years. The study participants will be&#xD;
      followed until disease progression or death. The study is expected to complete within 4&#xD;
      years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>long term</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>long term</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Craniotomy with total or partial removal of the brain tumor</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy to tumour bed and/or residual tumour</intervention_name>
    <description>60 Gy in 30 fractions over 6 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>75 mg/m2/day for entire period of radiotherapy&#xD;
150-200 mg/m2/day for 5 days every 28 days, 6 cycles total</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>4000 IU started 1 week before commencing radiotherapy and discontinued immediately after completing last chemotherapy cycle</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. Newly-diagnosed, histologically confirmed GBM&#xD;
&#xD;
          3. Surgical procedures: craniotomy with gross tumour resection or maximal debulking&#xD;
&#xD;
          4. Brain lesion suitable suitable for radical 3-DCRT/IMRT according to tumour location&#xD;
             and size.&#xD;
&#xD;
          5. Karnofsky performance status (KPS) &gt; 70 (ECOG/WHO 0-1)&#xD;
&#xD;
          6. No previous RT to brain&#xD;
&#xD;
          7. No serious comorbid condition&#xD;
&#xD;
          8. No treatment with biological response modifiers or cytotoxic agents within four weeks&#xD;
             prior to study entry&#xD;
&#xD;
          9. No participation in clinical trial using any investigational drug or device within&#xD;
             four weeks prior to study entry&#xD;
&#xD;
         10. No serious complication of malignant condition&#xD;
&#xD;
         11. No previous or concurrent malignancy at other sites, except cone biopsied in situ&#xD;
             carcinoma of the uterine cervix and adequately treated basal cell or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
         12. Adequate organ function as evidenced by the following peripheral blood counts or serum&#xD;
             chemistries at study entry:&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 Gm/dL&#xD;
&#xD;
               -  WBC count &gt; 4.0x109/L&#xD;
&#xD;
               -  Neutrophile count &gt; 1.5 cells x 109/L,&#xD;
&#xD;
               -  Platelet count &gt; 100 x 109/L,&#xD;
&#xD;
               -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
               -  Total bilirubin &lt; ULN (upper limit of normal)&#xD;
&#xD;
               -  AST/SGOT &lt; ULN&#xD;
&#xD;
               -  Calcium &lt; ULN&#xD;
&#xD;
         13. Ability to sign informed consent&#xD;
&#xD;
         14. Ability to attend follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Surgical procedures: only stereotactic biopsy&#xD;
&#xD;
          2. Brain lesion not suitable for 3-DCRT/IMRT&#xD;
&#xD;
          3. KPS &lt; 70 (ECOG/WHO &lt;2)&#xD;
&#xD;
          4. Previous RT to brain&#xD;
&#xD;
          5. Treatment with biological response modifiers or cytotoxic agents within four weeks&#xD;
             prior to study entry&#xD;
&#xD;
          6. Participation in clinical trial using any investigational drug or device within 7&#xD;
             weeks prior to study entry&#xD;
&#xD;
          7. Major surgical procedure within two weeks prior to study entry&#xD;
&#xD;
          8. Serious comorbid condition, inclusive but not limited to myocardial infarction within&#xD;
             previous six months, uncontrolled cardiac arrhythmias, uncontrolled angina pectoris,&#xD;
             active infection including acute hepatitis&#xD;
&#xD;
          9. Serious complication of malignant condition&#xD;
&#xD;
         10. Previous or concurrent malignancy&#xD;
&#xD;
         11. Known hypersensitivity to vitamin D&#xD;
&#xD;
         12. Inadequate organ function as evidenced by the following peripheral blood counts or&#xD;
             serum chemistries at study entry:&#xD;
&#xD;
               -  Hemoglobin &lt; 9.0 Gm/dL&#xD;
&#xD;
               -  WBC count &lt; 4.0x109/L&#xD;
&#xD;
               -  Neutrophile count &lt; 1.5 cells x 109/L,&#xD;
&#xD;
               -  Platelet count &lt; 100 x 109/L,&#xD;
&#xD;
               -  Creatinine &gt; 1.5 mg/dL&#xD;
&#xD;
               -  Total bilirubin &gt; ULN (upper limit of normal)&#xD;
&#xD;
               -  AST/SGOT &gt; ULN&#xD;
&#xD;
               -  Calcium &gt; ULN&#xD;
&#xD;
         13. Inability to sign informed consent&#xD;
&#xD;
         14. Psychological, familial, sociological or geographical conditions which do not permit&#xD;
             regular medical follow-up and compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantin Lavrenkov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Miedical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konstantin Lavrenkov, MD, PhD</last_name>
    <phone>+97286400537</phone>
    <email>constant@bgu.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olga Belochitski, MD</last_name>
    <phone>+97286400537</phone>
    <email>olgab@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Lavrenkov, MD, PhD</last_name>
      <phone>+97286400537</phone>
      <email>constant@bgu.ac.il</email>
    </contact>
    <contact_backup>
      <last_name>Olga Belochitski, MD</last_name>
      <phone>+97286400537</phone>
      <email>olgab@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Vladimir Gavrilov, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Belochitski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vladimir Merkin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>July 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>March 27, 2011</last_update_submitted>
  <last_update_submitted_qc>March 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Konstantin Lavrenkov, MD, PhD</name_title>
    <organization>Soroka University Medical Center</organization>
  </responsible_party>
  <keyword>glioblastoma multiforme</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

